Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Nat Rev Gastroenterol Hepatol. 2022 Feb 21;19(5):328–342. doi: 10.1038/s41575-022-00580-3

Table 1 |.

Currently available models for fibrolamellar carcinoma research

Model Type Species Method Strengths Limitations Refs
Published work
M-DP-1 In vivo Mouse CRISPR–Cas9-based genome editing
Transposon-mediated somatic gene transfer
In vivo tumour growth
Mimics many features of FLC
Slow tumorigenesis
Incomplete penetrance
Lacks fibrous bands
Lacks molecular features of FLC that are primate-specific
58
M-DP-2 In vivo Mouse CRISPR–Cas9-based genome editing In vivo tumour growth
Mimics many features of FLC
Slow tumorigenesis
Incomplete penetrance
Lacks fibrous bands
Lacks molecular features of FLC that are primate-specific
57
ZF-DP-1 In vivo Zebrafish Zebrafish DNAJ–PKAc over-expression In vivo model Evolutionarily more distant from humans than mice
Lacks molecular features specific to mammals and primates
96
PDX-1 In vivo Human Xenograft of patient-derived FLC tumour cells in immune-deficient mice In vivo tumour growth
Mimics most/all major features of FLC
Can be maintained stably in spheroid (3D) culture
Generally, tumour grown in host flank, not liver (non-orthotopic model)
Not metastatic from flank
36
PDX-2 to PDX-7 In vivo Human Xenograft of patient-derived FLC tumour cells in immune-deficient mice In vivo tumour growth
Mimics most/all major features of FLC
Derived directly from primary Liver tumours and metastases
Generally, tumour grown in host flank, not liver (non-orthotopic model)
Not metastatic from flank
97
HepG2-DP In vitro Human Lentiviral DP over-expression All human cells
Straightforward to culture and manipulate
No presence of cells from microenvironment
Hepatoblastoma background
Transformed cells
33,50
C3A-DP In vitro Human LentiviraL DP over-expression All human cells
Straightforward to culture and manipulate
No presence of cells from microenvironment
HCC background
Transformed cells
33
AML12-DP In vitro Mouse CRISPR–Cas9-based genome editing Primary hepatocytes
Straightforward to culture and manipulate
Mouse not human origin Transgenic for human TGFα 50,76,89
Unpublished or preliminary work
FLX-1 cell line In vitro Human Cell culture from PDX-1 xenograft model (Nearly) all human tumour cells
Established line that retains molecular features of FLC for multiple passages
Amenable to treatment and transfection
Limited (if any) microenvironmental signalling
Relatively slow growth
N. Bardeesy (personal communication)
Huh7-DP In vitro Human Lentiviral DP over-expression All human cells
Straightforward to culture and manipulate
No presence of cells from microenvironment
HCC background
Transformed cells
P.S., unpublished work
HEK293-DP In vitro Human CRISPR–
Cas9-based genome editing
All human cells
Straightforward to culture and manipulate
No presence of cells from microenvironment
Non-hepatic background
Transformed cells
95 (a preprint article)

All of these 16 in vitro and in vivo models currently in use for fibrolamellar carcinoma (FLC) research offer some strengths but also have key limitations, pointing to the critical need for improved models. DP, DNAJB1PRKACA; HCC, hepatocellular carcinoma; TGFα, transforming growth factor-α.